Vascular Tumors and Angiosarcomas
Vascular Tumors and Angiosarcomas is a research topic within Oncology. Science Explorer counts 19k research works in it since 1950. 8.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the research and clinical aspects of vascular tumors, particularly angiosarcoma and epithelioid hemangioendothelioma. It covers topics such as treatment outcomes, diagnostic markers, genetic alterations, risk factors, and therapeutic options for various types of vascular tumors. The cluster also explores the impact of radiation therapy on the development of angiosarcoma and the role of liver transplantation in managing hepatic angiosarcoma.
- Angiosarcoma
- Epithelioid Hemangioendothelioma
- Vascular Tumors
- Radiation-Associated Angiosarcoma
- Hepatic Angiosarcoma
- Kimura Disease
- Malignant Vascular Tumors
- Pseudomyogenic Hemangioendothelioma
- Metastatic Angiosarcomas
- Primary Liver Sarcomas
- Research works
- 19k fractional, since 1950
- In the world top 10%
- 1.7k per year above
- Top-10% rate
- 8.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +16% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Vascular Tumors and Angiosarcomas research?
By volume, the United States and China publish the most (655 and 459 works in 2022–2025).
By volume, 2022–2025
- 1 United States 655 works
- 2 China 459 works
- 3 India 288 works
- 4 Japan 229 works
- 5 Germany 92 works
- 6 Italy 90 works
- 7 Spain 87 works
- 8 United Kingdom 79 works
- 9 France 78 works
- 10 Brazil 72 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Vascular Tumors and Angiosarcomas research?
By volume in 2022–2025, All India Institute of Medical Sciences publishes the most Vascular Tumors and Angiosarcomas research, followed by The University of Texas MD Anderson Cancer Center and Sichuan University.
By volume, 2022–2025
- 1 All India Institute of Medical SciencesIndia 19 works
- 2 The University of Texas MD Anderson Cancer CenterUnited States 17 works
- 3 Sichuan UniversityChina 15 works
- 4 Cleveland ClinicUnited States 13 works
- 5 Memorial Sloan Kettering Cancer CenterUnited States 12 works
- 6 Post Graduate Institute of Medical Education and ResearchIndia 11 works
- 7 West China Hospital of Sichuan UniversityChina 11 works
- 8 Mohammed V UniversityMorocco 11 works
- 9 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 10 works
- 10 Mayo Clinic in ArizonaUnited States 10 works
Who are the leading researchers in Vascular Tumors and Angiosarcomas?
The most-cited researchers publishing on Vascular Tumors and Angiosarcomas include Marc Ladanyi, Steven A. Rosenberg and Armando Santoro.
- 1 Marc Ladanyi United States 3.1k citations
- 2 Steven A. Rosenberg United States 2.7k citations
- 3 Armando Santoro Italy 2.4k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Vascular Tumors and Angiosarcomas research done?
The largest centres of Vascular Tumors and Angiosarcomas research in 2022–2025 are Beijing (China), New Delhi (India), Tokyo (Japan) and Chengdu (China). Among places with at least 20 works in it, it is an unusually large share of all research in Cleveland.
Largest cities, 2022–2025
Where it is the local speciality
- ClevelandUS · 20.5 works5.1×
Location quotient: how much more of its research is in Vascular Tumors and Angiosarcomas than the world average.
Where is the best place to study Vascular Tumors and Angiosarcomas?
Among universities, judged by research, All India Institute of Medical Sciences, Post Graduate Institute of Medical Education and Research and Mohammed V University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | All India Institute of Medical SciencesIndia | 56.5 | 5.3% | 10.9× | 19 | +33.2% |
| 2 | Post Graduate Institute of Medical Education and ResearchIndia | 51.9 | 3.0% | 12.1× | 11 | +234.2% |
| 3 | Mohammed V UniversityMorocco | 48.3 | 0.0% | 9.5× | 11 | +194.4% |
| 4 | Harvard UniversityUnited States | 46.0 | 20.2% | 2.7× | 10 | +4.3% |
| 5 | Sichuan UniversityChina | 42.3 | 11.7% | 3.2× | 15 | +53.2% |
| 6 | Stanford UniversityUnited States | 36.3 | 17.2% | 2.5× | 9 | +23.3% |
| 7 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 33.4 | 10.8% | 3.7× | 10 | +49.3% |
| 8 | Institute of Medical SciencesIndia | 32.7 | 3.0% | 9.3× | 8 | +30.9% |
| 9 | Peking UniversityChina | 16.8 | 4.2% | 1.9× | 8 | +61.7% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Vascular Tumors and Angiosarcomas research growing?
Output in 2018–2022 was 16% higher than in 2013–2017, peaking in 2021. The fastest-growing topics are Vascular Tumors and Angiosarcomas.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.